Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus
| Autor: | Norio Tada, Seibu Mochizuki, Keiko Mochizuki, Ryoichi Nishide, Katsunori Ikewaki, Masafumi Iwasaki |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Apolipoprotein B Phosphodiesterase Inhibitors Endocrinology Diabetes and Metabolism Tetrazoles chemistry.chemical_compound Apolipoproteins E Endocrinology High-density lipoprotein Internal medicine medicine Humans Platelet activation Triglycerides Glycated Hemoglobin Apolipoprotein A-I biology Cholesterol Lipoprotein(a) Postprandial Period Dietary Fats Lipids Cyclic Nucleotide Phosphodiesterases Type 3 Cilostazol Phenotype Postprandial Diabetes Mellitus Type 2 chemistry 3' 5'-Cyclic-AMP Phosphodiesterases biology.protein lipids (amino acids peptides and proteins) Lipoproteins HDL Lipoprotein medicine.drug |
| Zdroj: | Metabolism. 51:1348-1354 |
| ISSN: | 0026-0495 |
| DOI: | 10.1053/meta.2002.35191 |
| Popis: | Low levels of high-density lipoproteins cholesterol (HDL-C) as well as impaired postprandial lipemia are known to be associated with the increased risk for coronary artery disease (CAD) in patients with type 2 diabetes mellitus (type 2 DM). HDL are heterogeneous in size and apolipoprotein composition. Recent evidence indicates that among the 2 major HDL subclasses, those without apolipoprotein A-II (LpA-I) are more antiatherogenic compared with those with apoA-II (LpA-I:A-II). Cilostazol, a novel selective phosphodiesterase type III inhibitor, has been shown to inhibit platelet activation and is also a potent vasodilator. Additionally, cilostazol has been shown to modulate lipoprotein profiles by raising HDL-C and lowering plasma triglyceride (TG) levels. The present study investigated the effect of cilostazol on HDL composition (LpA-I and LpA-I:A-II levels) and postprandial lipemia in patients with type 2 DM. Seventeen patients were given cilostazol 200 mg twice daily for 12 weeks. At weeks 0 and 12, fat tolerance tests (30 g/m(2)) were performed to assess postprandial lipemia. Plasma TG and remnant-like lipoprotein particles cholesterol (RLP-C) were significantly decreased by 17% and 26%, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect